Cargando…

Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1

BACKGROUND: With the development of regenerative medicine and tissue engineering technology, almost all stem cell therapy is efficacious for the treatment of premature ovarian failure (POF) or premature ovarian insufficiency (POI) animal models, whereas little stem cell therapy has been practiced in...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Boxian, Qian, Chunfeng, Ding, Chenyue, Meng, Qingxia, Zou, Qinyan, Li, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884777/
https://www.ncbi.nlm.nih.gov/pubmed/31783916
http://dx.doi.org/10.1186/s13287-019-1490-8
_version_ 1783474615878680576
author Huang, Boxian
Qian, Chunfeng
Ding, Chenyue
Meng, Qingxia
Zou, Qinyan
Li, Hong
author_facet Huang, Boxian
Qian, Chunfeng
Ding, Chenyue
Meng, Qingxia
Zou, Qinyan
Li, Hong
author_sort Huang, Boxian
collection PubMed
description BACKGROUND: With the development of regenerative medicine and tissue engineering technology, almost all stem cell therapy is efficacious for the treatment of premature ovarian failure (POF) or premature ovarian insufficiency (POI) animal models, whereas little stem cell therapy has been practiced in clinical settings. The underlying molecular mechanism and safety of stem cell treatment in POI are not fully understood. In this study, we explored whether fetal mesenchymal stem cells (fMSCs) from the liver restore ovarian function and whether melatonin membrane receptor 1 (MT1) acts as a regulator for treating POI disease. METHODS: We designed an in vivo model (chemotherapy-induced ovary damage) and an in vitro model (human ovarian granulosa cells (hGCs)) to understand the efficacy and molecular cues of fMSC treatment of POI. Follicle development was observed by H&E staining. The concentration of sex hormones in serum (E2, AMH, and FSH) and the concentration of oxidative and antioxidative metabolites and the enzymes MDA, SOD, CAT, LDH, GR, and GPx were measured by ELISA. Flow cytometry (FACS) was employed to detect the percentages of ROS and proliferation rates. mRNA and protein expression of antiapoptotic genes (SURVIVIN and BCL2), apoptotic genes (CASPASE-3 and CASPASE-9), and MT1 and its downstream genes (JNK1, PCNA, AMPK) were tested by qPCR and western blotting. MT1 siRNA and related antagonists were used to assess the mechanism. RESULTS: fMSC treatment prevented cyclophosphamide (CTX)-induced follicle loss and recovered sex hormone levels. Additionally, fMSCs significantly decreased oxidative damage, increased oxidative protection, improved antiapoptotic effects, and inhibited apoptotic genes in vivo and in vitro. Furthermore, fMSCs also upregulated MT1, JNK1, PCNA, and AMPK at the mRNA and protein levels. With MT1 knockdown or antagonist treatment in normal hGCs, the protein expression of JNK1, PCNA, and AMPK and the percentage of proliferation were impaired. CONCLUSIONS: fMSCs might play a crucial role in mediating follicular development in the POI mouse model and stimulating the activity of POI hGCs by targeting MT1.
format Online
Article
Text
id pubmed-6884777
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68847772019-12-03 Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1 Huang, Boxian Qian, Chunfeng Ding, Chenyue Meng, Qingxia Zou, Qinyan Li, Hong Stem Cell Res Ther Research BACKGROUND: With the development of regenerative medicine and tissue engineering technology, almost all stem cell therapy is efficacious for the treatment of premature ovarian failure (POF) or premature ovarian insufficiency (POI) animal models, whereas little stem cell therapy has been practiced in clinical settings. The underlying molecular mechanism and safety of stem cell treatment in POI are not fully understood. In this study, we explored whether fetal mesenchymal stem cells (fMSCs) from the liver restore ovarian function and whether melatonin membrane receptor 1 (MT1) acts as a regulator for treating POI disease. METHODS: We designed an in vivo model (chemotherapy-induced ovary damage) and an in vitro model (human ovarian granulosa cells (hGCs)) to understand the efficacy and molecular cues of fMSC treatment of POI. Follicle development was observed by H&E staining. The concentration of sex hormones in serum (E2, AMH, and FSH) and the concentration of oxidative and antioxidative metabolites and the enzymes MDA, SOD, CAT, LDH, GR, and GPx were measured by ELISA. Flow cytometry (FACS) was employed to detect the percentages of ROS and proliferation rates. mRNA and protein expression of antiapoptotic genes (SURVIVIN and BCL2), apoptotic genes (CASPASE-3 and CASPASE-9), and MT1 and its downstream genes (JNK1, PCNA, AMPK) were tested by qPCR and western blotting. MT1 siRNA and related antagonists were used to assess the mechanism. RESULTS: fMSC treatment prevented cyclophosphamide (CTX)-induced follicle loss and recovered sex hormone levels. Additionally, fMSCs significantly decreased oxidative damage, increased oxidative protection, improved antiapoptotic effects, and inhibited apoptotic genes in vivo and in vitro. Furthermore, fMSCs also upregulated MT1, JNK1, PCNA, and AMPK at the mRNA and protein levels. With MT1 knockdown or antagonist treatment in normal hGCs, the protein expression of JNK1, PCNA, and AMPK and the percentage of proliferation were impaired. CONCLUSIONS: fMSCs might play a crucial role in mediating follicular development in the POI mouse model and stimulating the activity of POI hGCs by targeting MT1. BioMed Central 2019-11-29 /pmc/articles/PMC6884777/ /pubmed/31783916 http://dx.doi.org/10.1186/s13287-019-1490-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Huang, Boxian
Qian, Chunfeng
Ding, Chenyue
Meng, Qingxia
Zou, Qinyan
Li, Hong
Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1
title Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1
title_full Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1
title_fullStr Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1
title_full_unstemmed Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1
title_short Fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting MT1
title_sort fetal liver mesenchymal stem cells restore ovarian function in premature ovarian insufficiency by targeting mt1
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884777/
https://www.ncbi.nlm.nih.gov/pubmed/31783916
http://dx.doi.org/10.1186/s13287-019-1490-8
work_keys_str_mv AT huangboxian fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1
AT qianchunfeng fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1
AT dingchenyue fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1
AT mengqingxia fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1
AT zouqinyan fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1
AT lihong fetallivermesenchymalstemcellsrestoreovarianfunctioninprematureovarianinsufficiencybytargetingmt1